Hypertensive disorders are a leading cause of maternal and neonatal morbidity and mortality worldwide. Preeclampsia is characterized by new onset hypertension and proteinuria after 20 weeks of gestation and can progress to eclampsia with seizures. It is diagnosed when blood pressure is ≥140/90 mmHg on two occasions at least 4 hours apart accompanied by ≥300mg protein in 24 hour urine or a urine protein creatinine ratio of >0.3. Treatment involves blood pressure control with medications like labetalol, nifedipine and magnesium sulfate to prevent seizures. Delivery is usually required to resolve preeclampsia though timing depends on gestational age and maternal/fetal stability. Close monitoring of mother and
1) The document discusses classifications of hypertension in pregnancy and definitions of preeclampsia. Preeclampsia is defined as hypertension and proteinuria or signs of multi-organ involvement without proteinuria.
2) Antihypertensive medications are prescribed during pregnancy to prevent maternal complications of severe hypertension like cardiovascular and cerebrovascular events, not to cure preeclampsia.
3) Common antihypertensives discussed for use in pregnancy include methyldopa, hydralazine, labetalol, and nifedipine. Their mechanisms of action, dosages, and potential side effects are reviewed.
This document provides guidelines and recommendations from the ACOG Task Force for the management of hypertension in pregnancy. It discusses classifications of hypertensive disorders in pregnancy and provides recommendations for predicting, preventing, and managing preeclampsia and HELLP syndrome. Key recommendations include initiating low-dose aspirin in women at high risk of preeclampsia, not using bed rest or restricted activity for prevention, and delivering women with severe features of preeclampsia or after 37 weeks with mild features. Expectant management is suggested with close monitoring for some cases.
This document discusses hypertensive disorders in pregnancy. It classifies hypertension into pre-existing (chronic) hypertension, pregnancy-induced hypertension (PIH), and superimposed pre-eclampsia/eclampsia. PIH includes transient hypertension, pre-eclampsia, and eclampsia. The document explores various theories of causation and provides details on pathological changes, diagnosis, screening tests, types of pre-eclampsia, complications, and treatment including prophylactic low-dose aspirin.
Carbetocin is a synthetic oxytocin analogue that is longer acting than oxytocin. It has a half-life of 40 minutes compared to 4-10 minutes for oxytocin. Studies show carbetocin is as effective or more effective than oxytocin in preventing postpartum hemorrhage following both vaginal and cesarean deliveries. It requires only a single dose rather than continuous infusion and does not cause uterine receptor desensitization like oxytocin. The WHO recommends carbetocin as an effective first-line uterotonic for preventing excessive bleeding after childbirth.
This document provides an overview of obstetric emergencies that may require intensive care admission. It defines obstetric emergencies as multi-disciplinary problems directly related to pregnancy. It discusses the physiological changes in pregnancy that increase risks and describes several types of emergencies including hemorrhagic (placenta previa, abruption, atony), hypertensive disorders, and thromboembolic complications. The document outlines assessment, management considerations, and treatment approaches for these time-critical maternal conditions in the ICU.
This document discusses the pharmacological management of preeclampsia with magnesium sulfate. It begins by outlining conditions treated with magnesium sulfate in obstetrics, including preterm labor, hypertensive disorders of pregnancy, and seizure prophylaxis. It then describes the pathophysiology of preeclampsia, mechanism of action of magnesium sulfate as an anticonvulsant and antihypertensive, potential interactions, adverse reactions, side effects, pharmacokinetics, and issues regarding drug binding. It concludes with improving communication around magnesium sulfate treatment and the application of related knowledge to clinical practice and nursing education.
Management of Cardiovascular Disease during PregnancyM A Hasnat
This document provides guidelines for managing cardiovascular diseases during pregnancy. It discusses physiological changes during pregnancy that impact the cardiovascular system. It also outlines a modified WHO classification system to assess maternal cardiovascular risk. Risk is stratified into 4 categories based on disease severity and impact on mortality and morbidity. Predictors of maternal and neonatal cardiovascular events are identified. Guidelines are provided for managing specific conditions like hypertension, as well as for timing and mode of delivery based on maternal risk. Drug therapies for hypertension are also discussed.
Hypertensive disorders are a leading cause of maternal and neonatal morbidity and mortality worldwide. Preeclampsia is characterized by new onset hypertension and proteinuria after 20 weeks of gestation and can progress to eclampsia with seizures. It is diagnosed when blood pressure is ≥140/90 mmHg on two occasions at least 4 hours apart accompanied by ≥300mg protein in 24 hour urine or a urine protein creatinine ratio of >0.3. Treatment involves blood pressure control with medications like labetalol, nifedipine and magnesium sulfate to prevent seizures. Delivery is usually required to resolve preeclampsia though timing depends on gestational age and maternal/fetal stability. Close monitoring of mother and
1) The document discusses classifications of hypertension in pregnancy and definitions of preeclampsia. Preeclampsia is defined as hypertension and proteinuria or signs of multi-organ involvement without proteinuria.
2) Antihypertensive medications are prescribed during pregnancy to prevent maternal complications of severe hypertension like cardiovascular and cerebrovascular events, not to cure preeclampsia.
3) Common antihypertensives discussed for use in pregnancy include methyldopa, hydralazine, labetalol, and nifedipine. Their mechanisms of action, dosages, and potential side effects are reviewed.
This document provides guidelines and recommendations from the ACOG Task Force for the management of hypertension in pregnancy. It discusses classifications of hypertensive disorders in pregnancy and provides recommendations for predicting, preventing, and managing preeclampsia and HELLP syndrome. Key recommendations include initiating low-dose aspirin in women at high risk of preeclampsia, not using bed rest or restricted activity for prevention, and delivering women with severe features of preeclampsia or after 37 weeks with mild features. Expectant management is suggested with close monitoring for some cases.
This document discusses hypertensive disorders in pregnancy. It classifies hypertension into pre-existing (chronic) hypertension, pregnancy-induced hypertension (PIH), and superimposed pre-eclampsia/eclampsia. PIH includes transient hypertension, pre-eclampsia, and eclampsia. The document explores various theories of causation and provides details on pathological changes, diagnosis, screening tests, types of pre-eclampsia, complications, and treatment including prophylactic low-dose aspirin.
Carbetocin is a synthetic oxytocin analogue that is longer acting than oxytocin. It has a half-life of 40 minutes compared to 4-10 minutes for oxytocin. Studies show carbetocin is as effective or more effective than oxytocin in preventing postpartum hemorrhage following both vaginal and cesarean deliveries. It requires only a single dose rather than continuous infusion and does not cause uterine receptor desensitization like oxytocin. The WHO recommends carbetocin as an effective first-line uterotonic for preventing excessive bleeding after childbirth.
This document provides an overview of obstetric emergencies that may require intensive care admission. It defines obstetric emergencies as multi-disciplinary problems directly related to pregnancy. It discusses the physiological changes in pregnancy that increase risks and describes several types of emergencies including hemorrhagic (placenta previa, abruption, atony), hypertensive disorders, and thromboembolic complications. The document outlines assessment, management considerations, and treatment approaches for these time-critical maternal conditions in the ICU.
This document discusses the pharmacological management of preeclampsia with magnesium sulfate. It begins by outlining conditions treated with magnesium sulfate in obstetrics, including preterm labor, hypertensive disorders of pregnancy, and seizure prophylaxis. It then describes the pathophysiology of preeclampsia, mechanism of action of magnesium sulfate as an anticonvulsant and antihypertensive, potential interactions, adverse reactions, side effects, pharmacokinetics, and issues regarding drug binding. It concludes with improving communication around magnesium sulfate treatment and the application of related knowledge to clinical practice and nursing education.
Management of Cardiovascular Disease during PregnancyM A Hasnat
This document provides guidelines for managing cardiovascular diseases during pregnancy. It discusses physiological changes during pregnancy that impact the cardiovascular system. It also outlines a modified WHO classification system to assess maternal cardiovascular risk. Risk is stratified into 4 categories based on disease severity and impact on mortality and morbidity. Predictors of maternal and neonatal cardiovascular events are identified. Guidelines are provided for managing specific conditions like hypertension, as well as for timing and mode of delivery based on maternal risk. Drug therapies for hypertension are also discussed.
Here are a few key things we can do:
1. Provide thorough preconception counseling to assess risk and optimize medical condition before pregnancy if possible.
2. Ensure careful multidisciplinary antenatal care involving cardiologists, obstetricians, anesthesiologists to monitor for complications.
3. Plan delivery carefully considering hemodynamic changes, with options for early delivery or C-section if needed.
4. Be vigilant for dangerous periods like labor/delivery when changes in volume and pressure occur abruptly. Have low threshold for ICU admission.
5. Educate patients and families on warning signs and ensure close postpartum follow up as this is a high risk period.
6.
The document discusses hypertensive disorders of pregnancy, which are a leading cause of maternal mortality. Gestational hypertension and preeclampsia are characterized by high blood pressure and proteinuria developing after 20 weeks of pregnancy. Preeclampsia can progress to eclampsia, which involves seizures. Risk factors include nulliparity, obesity, and family history. Symptoms include headaches and visual changes. Complications affect both mother and baby. Treatment involves controlling blood pressure, delivering the baby, and administering magnesium sulfate to prevent seizures.
This document discusses cardiac diseases in pregnancy. It begins with the epidemiology and classification of heart diseases. It then covers the normal cardiovascular alterations in pregnancy, the effects of pregnancy on heart diseases and vice versa. It provides details on diagnosing and managing heart diseases in pregnancy, including specific cardiac conditions and complications like arrhythmias and heart failure. Close monitoring is needed during pregnancy for women with cardiac issues due to risks of maternal mortality, preterm delivery, fetal growth problems, and congenital heart defects in the baby.
Management of the critically ill obstetric patient.prof.salahSalah Roshdy AHMED
The document discusses the management of critically ill obstetric patients. It begins by outlining the leading causes of ICU admission for pregnant women as preeclampsia and hemorrhage. It then discusses important considerations when treating critically ill obstetric patients, such as accounting for normal physiological changes of pregnancy and treating the mother and fetus. The document proceeds to discuss specific multi-organ system diseases that can occur in critically ill pregnant patients such as ARDS, shock, and DIC. It concludes by focusing on management of hemorrhage, preeclampsia, and DIC.
Hypertensive disorders in pregnancy recent guidelines fogsi 2014Dr Meenakshi Sharma
This document discusses guidelines for hypertensive disorders in pregnancy from FOGSI 2014. Some key points:
1. Hypertension complicates 5-10% of pregnancies and is a leading cause of maternal mortality. Preeclampsia can develop in women with a history of the condition in 13-53% of future pregnancies.
2. Diagnosis of hypertensive disorders in pregnancy includes gestational hypertension (blood pressure over 140/90 without proteinuria after 20 weeks), preeclampsia (same with proteinuria), and chronic hypertension (high blood pressure before pregnancy).
3. Treatment for mild to moderate hypertension in pregnancy focuses on oral antihypertensives like labetalol and
1) Recent research has found that fetal fibronectin testing and ultrasound assessment of cervical length can help predict preterm birth in symptomatic women, though fetal fibronectin may have limited accuracy within 7 days.
2) Nifedipine and atosiban appear to be effective tocolytic options with fewer side effects than alternatives like ritodrine and indomethacin. Tocolysis is generally not continued past 48 hours except in special cases.
3) Antenatal corticosteroids between 24-34 weeks can help reduce fetal morbidity from preterm birth. Routine antibiotics without ruptured membranes do not prolong pregnancy or improve neonatal outcomes. Bed rest does not lower preterm
This document provides information on vaginal birth after caesarean (VBAC) including definitions, risks, guidelines and a case study. It defines key terms like VBAC, discusses risks to mother and baby like uterine rupture, and outlines factors that increase unsuccessful VBAC rates. Antenatal assessment and counseling guidelines are provided. Intrapartum guidelines include trial of labour duration and signs of complications. A case study describes a uterine rupture during labour and allegations of delayed caesarean section.
Lecture by Dr Sujoy Dasgupta in BOGSCON 2015, the Annual Conference of Bengal Obstetric and Gynaecological Society, held at Hotel Novotel, Kolkata in January, 2015; where he had been invited as FACULTY to deliver his lecture
Thrombophilia & Thromboembolism in Pregnancy & PuerperiumJagannath Mishra
Pregnancy increases the risk of venous thromboembolism (VTE) due to changes in coagulation factors and blood flow. This document provides definitions and discusses the risk, diagnosis, and management of VTE during pregnancy and postpartum. It recommends assessing all pregnant women for risk factors and stratifying treatment based on a woman's prior VTE history and any thrombophilias. High-risk women should receive low molecular weight heparin thromboprophylaxis during pregnancy and for 6 weeks postpartum, while intermediate-risk women may receive shorter postpartum prophylaxis. Low molecular weight heparins are preferred over unfractionated heparin for safety reasons.
Venous thromboembolism is a major cause of maternal mortality. Pregnancy increases the risk of deep vein thrombosis due to physiological changes that cause venous stasis and a hypercoagulable state. The risk is highest in the antenatal period and after cesarean delivery. Diagnosis involves Doppler ultrasound or CT scan and treatment involves low molecular weight heparin for at least 6 weeks. Prevention through thromboprophylaxis is recommended for women with prior VTE or thrombophilia.
This document discusses the diagnosis and management of hypertensive disorders in pregnancy. It defines various types of hypertension including gestational hypertension, preeclampsia, and eclampsia. It covers the signs and symptoms, potential complications, risk factors, diagnostic tests, and treatment approaches including antihypertensive medications and magnesium sulfate administration. Treatment involves controlling blood pressure, preventing seizures, administering steroids to promote fetal lung maturity, and carefully monitoring fluid balance, with the goal of optimizing outcomes for both the mother and baby.
Management of postterm pregnancy involves balancing risks to the fetus and mother. Postterm is defined as past 42 weeks gestation. Accurately dating the pregnancy is important to avoid false diagnosis. Risks to the fetus include stillbirth, meconium aspiration, and macrosomia. Risks to the mother include dystocia and infection. Studies show inducing labor at 41 weeks reduces stillbirths without increasing C-sections. Methods of antenatal testing after 41 weeks are debated, though monitoring is recommended. While an unfavorable cervix was viewed as a risk factor for C-section, recent evidence suggests underlying issues may be more important. Further research is needed to determine the optimal time for induction to minimize risks
Pprom by dr alka mukherjee dr apurva mukherjee nagpur indiaalka mukherjee
Preterm premature rupture of the membranes (PPROM) is a pregnancy complication. In this condition, the sac (amniotic membrane) surrounding your baby breaks (ruptures) before week 37 of pregnancy. Once the sac breaks, you have an increased risk for infection. You also have a higher chance of having your baby born early.
In most cases of PPROM, the cause is not known.
These things may increase risk:
• Having a preterm birth in a previous pregnancy
• Having an infection in your reproductive system
• Vaginal bleeding during pregnancy
• Smoking during pregnancy
Symptoms can occur a bit differently in each pregnancy. They can include:
• A sudden gush of fluid from your vagina
• Leaking of fluid from your vagina
• A feeling of wetness in your vagina or underwear
Call your healthcare provider right away if you have these symptoms.
The symptoms of this health problem may be similar to symptoms of other conditions. See your healthcare provider for a diagnosis.
Diagnosis
• pH (acid-base) balance testing. The pH balance of amniotic fluid is different from vaginal fluid and urine. Your healthcare provider will put the fluid on a test strip to check the balance.
• Looking at a sample under a microscope. When amniotic fluid is dry, it has a fern-like pattern.
• ultrasound exam. This is done to check the amount of amniotic fluid around baby.
This document discusses cardiac disease in pregnancy. The major causes of cardiac death over the last 10 years are cardiomyopathy, myocardial infarction, and ischemic heart disease. Physiological adaptations to pregnancy include increases in blood volume, stroke volume, heart rate, and cardiac output. Labor further increases cardiac output. Examination may reveal murmurs. Echocardiography is the preferred investigation. Risks are assessed based on factors like pulmonary hypertension and cardiac function. Management involves a multidisciplinary team and monitoring for decompensation. Risks vary for different cardiac lesions and are managed accordingly, such as with endocarditis prophylaxis.
This document discusses dengue fever, including its prevalence, transmission, clinical presentation, diagnosis, and management, with a focus on dengue in pregnancy. It notes that 40% of the world's population lives in dengue-prone areas and there are an estimated 100 million infections annually. Early detection and medical care reduces the fatality rate from 20% to below 1%. The document outlines the warning signs of severe dengue, diagnostic tests, fluid resuscitation protocols, and emphasizes the importance of prompt diagnosis and management to reduce morbidity and mortality in both mothers and infants.
This document discusses the causes, diagnosis, and management of pregnancy-induced hypertension (PIH) and eclampsia. PIH is a multi-system disorder characterized by high blood pressure and proteinuria after 20 weeks of gestation. Eclampsia is a complication of PIH defined by the presence of convulsions. The document outlines classification of PIH severity, signs and symptoms of eclampsia, risk factors, effects on mother and fetus, and steps for diagnosis and management including controlling blood pressure, seizures, and delivering the baby. Early detection through antenatal care and timely management are important to reduce risks of eclampsia and maternal mortality.
Labour is considered prolonged if it lasts more than 12 hours. It can be caused by issues with the passageway (pelvis), passenger (baby), powers (contractions), or psyche (mental state). Prolonged labour risks maternal and fetal complications if neglected. Close monitoring is needed to detect obstruction early. Treatment depends on fetal viability but may include resuscitating the mother, controlling infection, relieving obstruction via c-section, and post-delivery care like antibiotics and bladder drainage. Abnormal uterine contractions can also prolong labour and are treated with oxytocin.
A comprehensive overview of hypertensive disorders in pregnancy with its complications and management. Mainly focused on gestational hypertension, preeclampsia and eclampsia.
This document summarizes evidence on the use of antenatal corticosteroids (ACS) to improve outcomes for preterm infants. It finds that a single course of betamethasone or dexamethasone between 23-34 weeks reduces rates of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and mortality. Multiple courses increase risks of fetal growth restriction. Benefits are seen 1-7 days after treatment. ACS is now recommended for women at risk of preterm birth from 24-34 weeks to improve neonatal outcomes.
This document discusses hypertensive disorders of pregnancy including gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome. Key points:
1. Preeclampsia affects 10-12% of pregnancies and is a leading cause of maternal death worldwide. It involves new onset hypertension and proteinuria after 20 weeks.
2. Diagnosis, monitoring, and management involves frequent blood pressure monitoring, urine and blood tests. Delivery is usually indicated for worsening conditions or after 37 weeks.
3. Magnesium sulfate is used for seizure prophylaxis in preeclampsia patients and blood pressure control is important for reducing maternal risks while allowing further fetal growth.
This document summarizes renal disorders that can occur in pregnancy. It discusses the normal physiologic changes in pregnancy that affect the kidneys as well as specific disorders like preeclampsia, hypertension, AKI, lupus nephritis, diabetic nephropathy, and nephrotic syndrome. It provides diagnostic criteria and recommendations for management and treatment for many of these conditions to help support healthy pregnancies and outcomes.
Here are a few key things we can do:
1. Provide thorough preconception counseling to assess risk and optimize medical condition before pregnancy if possible.
2. Ensure careful multidisciplinary antenatal care involving cardiologists, obstetricians, anesthesiologists to monitor for complications.
3. Plan delivery carefully considering hemodynamic changes, with options for early delivery or C-section if needed.
4. Be vigilant for dangerous periods like labor/delivery when changes in volume and pressure occur abruptly. Have low threshold for ICU admission.
5. Educate patients and families on warning signs and ensure close postpartum follow up as this is a high risk period.
6.
The document discusses hypertensive disorders of pregnancy, which are a leading cause of maternal mortality. Gestational hypertension and preeclampsia are characterized by high blood pressure and proteinuria developing after 20 weeks of pregnancy. Preeclampsia can progress to eclampsia, which involves seizures. Risk factors include nulliparity, obesity, and family history. Symptoms include headaches and visual changes. Complications affect both mother and baby. Treatment involves controlling blood pressure, delivering the baby, and administering magnesium sulfate to prevent seizures.
This document discusses cardiac diseases in pregnancy. It begins with the epidemiology and classification of heart diseases. It then covers the normal cardiovascular alterations in pregnancy, the effects of pregnancy on heart diseases and vice versa. It provides details on diagnosing and managing heart diseases in pregnancy, including specific cardiac conditions and complications like arrhythmias and heart failure. Close monitoring is needed during pregnancy for women with cardiac issues due to risks of maternal mortality, preterm delivery, fetal growth problems, and congenital heart defects in the baby.
Management of the critically ill obstetric patient.prof.salahSalah Roshdy AHMED
The document discusses the management of critically ill obstetric patients. It begins by outlining the leading causes of ICU admission for pregnant women as preeclampsia and hemorrhage. It then discusses important considerations when treating critically ill obstetric patients, such as accounting for normal physiological changes of pregnancy and treating the mother and fetus. The document proceeds to discuss specific multi-organ system diseases that can occur in critically ill pregnant patients such as ARDS, shock, and DIC. It concludes by focusing on management of hemorrhage, preeclampsia, and DIC.
Hypertensive disorders in pregnancy recent guidelines fogsi 2014Dr Meenakshi Sharma
This document discusses guidelines for hypertensive disorders in pregnancy from FOGSI 2014. Some key points:
1. Hypertension complicates 5-10% of pregnancies and is a leading cause of maternal mortality. Preeclampsia can develop in women with a history of the condition in 13-53% of future pregnancies.
2. Diagnosis of hypertensive disorders in pregnancy includes gestational hypertension (blood pressure over 140/90 without proteinuria after 20 weeks), preeclampsia (same with proteinuria), and chronic hypertension (high blood pressure before pregnancy).
3. Treatment for mild to moderate hypertension in pregnancy focuses on oral antihypertensives like labetalol and
1) Recent research has found that fetal fibronectin testing and ultrasound assessment of cervical length can help predict preterm birth in symptomatic women, though fetal fibronectin may have limited accuracy within 7 days.
2) Nifedipine and atosiban appear to be effective tocolytic options with fewer side effects than alternatives like ritodrine and indomethacin. Tocolysis is generally not continued past 48 hours except in special cases.
3) Antenatal corticosteroids between 24-34 weeks can help reduce fetal morbidity from preterm birth. Routine antibiotics without ruptured membranes do not prolong pregnancy or improve neonatal outcomes. Bed rest does not lower preterm
This document provides information on vaginal birth after caesarean (VBAC) including definitions, risks, guidelines and a case study. It defines key terms like VBAC, discusses risks to mother and baby like uterine rupture, and outlines factors that increase unsuccessful VBAC rates. Antenatal assessment and counseling guidelines are provided. Intrapartum guidelines include trial of labour duration and signs of complications. A case study describes a uterine rupture during labour and allegations of delayed caesarean section.
Lecture by Dr Sujoy Dasgupta in BOGSCON 2015, the Annual Conference of Bengal Obstetric and Gynaecological Society, held at Hotel Novotel, Kolkata in January, 2015; where he had been invited as FACULTY to deliver his lecture
Thrombophilia & Thromboembolism in Pregnancy & PuerperiumJagannath Mishra
Pregnancy increases the risk of venous thromboembolism (VTE) due to changes in coagulation factors and blood flow. This document provides definitions and discusses the risk, diagnosis, and management of VTE during pregnancy and postpartum. It recommends assessing all pregnant women for risk factors and stratifying treatment based on a woman's prior VTE history and any thrombophilias. High-risk women should receive low molecular weight heparin thromboprophylaxis during pregnancy and for 6 weeks postpartum, while intermediate-risk women may receive shorter postpartum prophylaxis. Low molecular weight heparins are preferred over unfractionated heparin for safety reasons.
Venous thromboembolism is a major cause of maternal mortality. Pregnancy increases the risk of deep vein thrombosis due to physiological changes that cause venous stasis and a hypercoagulable state. The risk is highest in the antenatal period and after cesarean delivery. Diagnosis involves Doppler ultrasound or CT scan and treatment involves low molecular weight heparin for at least 6 weeks. Prevention through thromboprophylaxis is recommended for women with prior VTE or thrombophilia.
This document discusses the diagnosis and management of hypertensive disorders in pregnancy. It defines various types of hypertension including gestational hypertension, preeclampsia, and eclampsia. It covers the signs and symptoms, potential complications, risk factors, diagnostic tests, and treatment approaches including antihypertensive medications and magnesium sulfate administration. Treatment involves controlling blood pressure, preventing seizures, administering steroids to promote fetal lung maturity, and carefully monitoring fluid balance, with the goal of optimizing outcomes for both the mother and baby.
Management of postterm pregnancy involves balancing risks to the fetus and mother. Postterm is defined as past 42 weeks gestation. Accurately dating the pregnancy is important to avoid false diagnosis. Risks to the fetus include stillbirth, meconium aspiration, and macrosomia. Risks to the mother include dystocia and infection. Studies show inducing labor at 41 weeks reduces stillbirths without increasing C-sections. Methods of antenatal testing after 41 weeks are debated, though monitoring is recommended. While an unfavorable cervix was viewed as a risk factor for C-section, recent evidence suggests underlying issues may be more important. Further research is needed to determine the optimal time for induction to minimize risks
Pprom by dr alka mukherjee dr apurva mukherjee nagpur indiaalka mukherjee
Preterm premature rupture of the membranes (PPROM) is a pregnancy complication. In this condition, the sac (amniotic membrane) surrounding your baby breaks (ruptures) before week 37 of pregnancy. Once the sac breaks, you have an increased risk for infection. You also have a higher chance of having your baby born early.
In most cases of PPROM, the cause is not known.
These things may increase risk:
• Having a preterm birth in a previous pregnancy
• Having an infection in your reproductive system
• Vaginal bleeding during pregnancy
• Smoking during pregnancy
Symptoms can occur a bit differently in each pregnancy. They can include:
• A sudden gush of fluid from your vagina
• Leaking of fluid from your vagina
• A feeling of wetness in your vagina or underwear
Call your healthcare provider right away if you have these symptoms.
The symptoms of this health problem may be similar to symptoms of other conditions. See your healthcare provider for a diagnosis.
Diagnosis
• pH (acid-base) balance testing. The pH balance of amniotic fluid is different from vaginal fluid and urine. Your healthcare provider will put the fluid on a test strip to check the balance.
• Looking at a sample under a microscope. When amniotic fluid is dry, it has a fern-like pattern.
• ultrasound exam. This is done to check the amount of amniotic fluid around baby.
This document discusses cardiac disease in pregnancy. The major causes of cardiac death over the last 10 years are cardiomyopathy, myocardial infarction, and ischemic heart disease. Physiological adaptations to pregnancy include increases in blood volume, stroke volume, heart rate, and cardiac output. Labor further increases cardiac output. Examination may reveal murmurs. Echocardiography is the preferred investigation. Risks are assessed based on factors like pulmonary hypertension and cardiac function. Management involves a multidisciplinary team and monitoring for decompensation. Risks vary for different cardiac lesions and are managed accordingly, such as with endocarditis prophylaxis.
This document discusses dengue fever, including its prevalence, transmission, clinical presentation, diagnosis, and management, with a focus on dengue in pregnancy. It notes that 40% of the world's population lives in dengue-prone areas and there are an estimated 100 million infections annually. Early detection and medical care reduces the fatality rate from 20% to below 1%. The document outlines the warning signs of severe dengue, diagnostic tests, fluid resuscitation protocols, and emphasizes the importance of prompt diagnosis and management to reduce morbidity and mortality in both mothers and infants.
This document discusses the causes, diagnosis, and management of pregnancy-induced hypertension (PIH) and eclampsia. PIH is a multi-system disorder characterized by high blood pressure and proteinuria after 20 weeks of gestation. Eclampsia is a complication of PIH defined by the presence of convulsions. The document outlines classification of PIH severity, signs and symptoms of eclampsia, risk factors, effects on mother and fetus, and steps for diagnosis and management including controlling blood pressure, seizures, and delivering the baby. Early detection through antenatal care and timely management are important to reduce risks of eclampsia and maternal mortality.
Labour is considered prolonged if it lasts more than 12 hours. It can be caused by issues with the passageway (pelvis), passenger (baby), powers (contractions), or psyche (mental state). Prolonged labour risks maternal and fetal complications if neglected. Close monitoring is needed to detect obstruction early. Treatment depends on fetal viability but may include resuscitating the mother, controlling infection, relieving obstruction via c-section, and post-delivery care like antibiotics and bladder drainage. Abnormal uterine contractions can also prolong labour and are treated with oxytocin.
A comprehensive overview of hypertensive disorders in pregnancy with its complications and management. Mainly focused on gestational hypertension, preeclampsia and eclampsia.
This document summarizes evidence on the use of antenatal corticosteroids (ACS) to improve outcomes for preterm infants. It finds that a single course of betamethasone or dexamethasone between 23-34 weeks reduces rates of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and mortality. Multiple courses increase risks of fetal growth restriction. Benefits are seen 1-7 days after treatment. ACS is now recommended for women at risk of preterm birth from 24-34 weeks to improve neonatal outcomes.
This document discusses hypertensive disorders of pregnancy including gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome. Key points:
1. Preeclampsia affects 10-12% of pregnancies and is a leading cause of maternal death worldwide. It involves new onset hypertension and proteinuria after 20 weeks.
2. Diagnosis, monitoring, and management involves frequent blood pressure monitoring, urine and blood tests. Delivery is usually indicated for worsening conditions or after 37 weeks.
3. Magnesium sulfate is used for seizure prophylaxis in preeclampsia patients and blood pressure control is important for reducing maternal risks while allowing further fetal growth.
This document summarizes renal disorders that can occur in pregnancy. It discusses the normal physiologic changes in pregnancy that affect the kidneys as well as specific disorders like preeclampsia, hypertension, AKI, lupus nephritis, diabetic nephropathy, and nephrotic syndrome. It provides diagnostic criteria and recommendations for management and treatment for many of these conditions to help support healthy pregnancies and outcomes.
This document discusses preeclampsia, a hypertensive disorder that occurs during pregnancy. It defines preeclampsia as hypertension and proteinuria arising after 20 weeks of gestation. Preeclampsia can progress to eclampsia, which involves seizures. Risk factors include primigravidity and family history. Symptoms include headaches and visual disturbances. Diagnosis involves blood pressure monitoring and urine analysis. Delivery is the only cure for preeclampsia. Management focuses on controlling blood pressure, monitoring the fetus, and timely delivery. Complications for the mother include eclampsia, HELLP syndrome, and stroke, while risks for the baby include growth restriction and stillbirth.
1) Pregnancy induced hypertension complicates 5-10% of pregnancies and is a leading cause of maternal mortality. It includes gestational hypertension, preeclampsia, and chronic hypertension.
2) Preeclampsia is diagnosed when a woman develops high blood pressure and protein in the urine after 20 weeks of pregnancy. Symptoms can include headaches, abdominal pain, and vision changes.
3) Management of mild preeclampsia involves outpatient monitoring while management of severe preeclampsia requires hospitalization, magnesium sulfate treatment, and sometimes antihypertensive drugs. Delivery is the definitive treatment when the condition becomes severe or the pregnancy reaches term.
Pregnancy-induced hypertension (PIH) is a condition characterized by new onset hypertension after 20 weeks of gestation without prior chronic hypertension. It can range from mild to severe preeclampsia and eclampsia. Severe PIH is associated with multiple organ involvement and risks to both mother and baby. Care involves careful monitoring, controlling blood pressure, delivering the baby when term, and preventing and treating seizures with magnesium sulfate. Anesthetic management focuses on regional techniques like epidural anesthesia to control blood pressure, while preparing for potential difficulties like airway edema during general anesthesia if needed.
1) The document discusses pregnancy induced hypertension, its classification, diagnosis, and management. It defines four types of hypertensive disorders in pregnancy: gestational hypertension, preeclampsia-eclampsia (mild and severe), superimposed preeclampsia-eclampsia, and chronic (preexisting) hypertension.
2) For diagnosis of hypertension in pregnancy, blood pressure must exceed 140/90 mmHg. Diagnosis of mild or severe preeclampsia depends on blood pressure levels and presence of proteinuria.
3) Management of mild preeclampsia can involve outpatient monitoring with regular visits or inpatient monitoring with maternal and fetal monitoring and treatment if signs worsen.
Preeclampsia is a hypertensive disorder of pregnancy that affects around 6% of pregnancies. It can range from mild to life-threatening, with severe cases involving seizures (eclampsia), HELLP syndrome, or fetal growth restriction. The cause is unknown but may involve placental ischemia and genetic factors. Diagnosis requires new-onset hypertension and proteinuria after 20 weeks gestation. Treatment of mild preeclampsia typically involves delivery after 37 weeks, while severe preeclampsia often requires expedited delivery. Eclampsia is the occurrence of seizures in preeclampsia, treated with magnesium sulfate or other anticonvulsants and delivery after maternal stabilization.
This document discusses hypertensive disorders in pregnancy including preeclampsia. It defines preeclampsia as a pregnancy-specific syndrome characterized by placental dysfunction and maternal systemic inflammation. Key signs include new onset hypertension and proteinuria after 20 weeks of gestation. Preeclampsia is more common in first time mothers and can lead to serious maternal and fetal complications if not monitored closely and managed properly. Treatment involves monitoring for signs of worsening, administering antihypertensives and magnesium sulfate for seizure prevention, delivering the baby if the condition becomes severe, and careful postpartum care and monitoring of both mother and baby.
This document discusses various topics related to renal physiology and disease in pregnancy. It begins with an overview of the normal adaptations the kidneys undergo during pregnancy, including increases in kidney size, glomerular filtration rate (GFR), and decreased creatinine and blood urea nitrogen levels. It then covers specific topics like urinary tract infections (UTIs), hypertensive disorders of pregnancy, acute kidney injury, and chronic kidney disease in the context of pregnancy. For each topic, it provides details on pathogenesis, screening, treatment approaches, and management considerations for caring for pregnant patients with renal conditions.
Diabetes mellitus and thyroid diseases can impact pregnancy. The presentation discussed diabetes mellitus, its classification and effects during pregnancy. It can increase risks for the mother like hypertension and risks for the baby like macrosomia. Screening and care involve monitoring blood sugar via tests and working with a team. Gestational diabetes requires diet control or possibly insulin. Thyroid diseases like thyrotoxicosis also impact pregnancy and require treatment to control the condition and prevent risks. Care involves monitoring and treating any thyroid abnormalities in the mother or baby.
This document discusses jaundice in pregnancy. It notes that clinical jaundice occurs in 1 in 1000 pregnancies in India. The most common cause of jaundice in pregnancy is viral hepatitis. Mortality from infectious hepatitis is 3.5 times higher in pregnancy compared to non-pregnant women. Some of the specific causes of jaundice discussed in more detail include hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome, acute fatty liver of pregnancy, and various types of viral hepatitis. The document also discusses physiological changes in the liver during pregnancy and provides guidelines for diagnosis and management of different conditions that can cause jaundice.
The document provides protocols and guidelines for the Department of Obstetrics including definitions, classifications, investigations, and management guidelines for various obstetric conditions. It covers protocols for pre-eclampsia and eclampsia, liver diseases in pregnancy, deep venous thrombosis in pregnancy, preterm labour, preterm PROM, breech presentation, APH, induction of labour, normal labour and delivery, PPH, umbilical cord prolapse, Rh prophylaxis, and GDM. The department aims to provide high quality, empathetic and research-based care through comprehensive training and by reviewing and creating protocols according to population needs.
This document discusses hypertensive disorders in pregnancy, which remain a leading cause of maternal mortality in Uganda. It defines various hypertensive disorders including chronic hypertension, gestational hypertension, preeclampsia, and HELLP syndrome. Risk factors, pathogenesis, clinical features, investigations, and management are described. Severe preeclampsia is treated with antihypertensive drugs like hydralazine to control blood pressure and delivery of the baby to resolve the condition. Hypertensive disorders continue to have high mortality and morbidity rates in Uganda.
HYPERTENSIVE DISORDERS OF PREGNANCY.pptxssuser52ada61
This document discusses hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, chronic hypertension, and preeclampsia superimposed on chronic hypertension. It covers classification, risk factors, pathogenesis, clinical features, investigations, management including antihypertensive treatment and timing of delivery, complications, and key takeaways on reducing morbidity and mortality through timely identification and management.
Pregnancy after kidney transplantation can be successful but carries increased risks for both mother and baby. Close monitoring by a multidisciplinary team is important. It is generally recommended to wait at least one year after transplantation for stable graft function before attempting pregnancy. Medications like mycophenolate and mTOR inhibitors should be discontinued or switched prior to conception due to teratogenic risks. Counseling discusses the impact of pregnancy on the allograft and risks of maternal complications like preeclampsia and fetal issues such as prematurity. Careful management of immunosuppression levels, blood pressure, and infections can help support a healthy pregnancy outcome.
This document discusses renal disease and pregnancy. It begins by outlining the normal physiological changes that occur in the kidney during pregnancy, including increased renal plasma flow, GFR, and dilatation of the collecting system. It then covers pregnancy-induced hypertension, including gestational hypertension, chronic hypertension, preeclampsia, and chronic hypertension with superimposed preeclampsia. The document also discusses acute kidney injury in pregnancy and chronic kidney disease and pregnancy. It provides details on diagnosis and management of various conditions.
A 38 slide power-point presentation for medical students years 4 or 5. The idea to familiarize with classification, clinical features, diagnosis and management.
This document discusses hypertension in pregnancy. It covers how to measure blood pressure in pregnant women, the diagnostic criteria for gestational hypertension and preeclampsia, risk factors, pathophysiology, tests to run, management including medications and delivery timing, and postpartum care. Preeclampsia is a leading cause of maternal and infant morbidity and mortality whose exact causes remain unknown but may be related to placental dysfunction and an exaggerated maternal inflammatory response.
Similar to Preeclampsia- Obstetrics& Gynaecology (20)
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
3. DEFINITION
Preeclampsia is a multisystem disorder of
unknown etiology characterized by
development of hypertension to the extent of
140/90 mm Hg or more with proteinuria after
the 20th week in a privousley normotensive
and non proteinuric women
4. Incidence
Incidence of preeclampsia in hospital practice
varies widely from 5% to 15%
Primigravida is about 10%
Multigravida 5%
5. Causes
1)Failure of trophoplast invasion
2)Increased production of antiangiogenic
factors
3)Coagulation disturbance
4)Altered vascular reactivity
5) Retention of sodium
7. Risk factor
Primigravida
Family history
Placenatl abnormality –hyperplacentosis –
excessive exposure to chorionic villi
-Placental ischemia
Obesity – BMI more than 35 kg/m2 , insulin
resistence
Pre existing vascular disease
New paternity , pregnancy following ART
Thrombophilias
9. Clinical types
Non severe – blood pressure of more than
140/90 mmHg but less than 160 mm Hg
systolic or 110mmHg diastolic without
signficant proteinuria .
Severe – peristent systolic blood pressure
above or equal to 160 mmHg or diastolic
pressure above 110mmHg
Proteinuria
Oliguria less than 400mL /24hour
10. Platelet count less than 100,000/mm3
Elevated liver enzyme
Cerebral or visual disturbance
Persistent severe epigastric pain
Retinal hemorrhage ,exudates
Intrauterine growth restriction of the fetus
Pulmonary edema
Serum creatinine more than1.1 mg /dl
11. Symptoms
1)Mild symptoms
2)Alarming symptoms-headache
Disturbed sleep
Diminished urinary output – less then 400ml
Epigastric pain – results from hepatocelluler
necrosis and stretching of liver capsule
Eye symptoms – blurring , scotomata , dimness
of vision on at times complete blindness vision is
usually regained within 4-6 weeks following
delivery due to spasm of retinal vessel
12. Investigation
Urine – presence of hyaline cast , epithelial
cells or even few red blood cell , protein
Ophthalmoscopic examination – retinal
edema , constriction of the arterioles ,
alteration of normal ratio of veins : arteriole
diameter from 3:2, 3:1 ,hemorrhage .
13. Blood values – serum uric acid level of more
than 4.5mg /dl , serum creatinine level may
be more than 1mg /dl , thrombocytopenia ,
hepatic enzyme level may be increased.
Antenatal fetal monitoring –daily fetal kick
count ,ultrasonography liquor pockets ,
cardiotocography , umbilical artery flow
velocimetry and biophysical profile
14. Prediction and prevention of
pre eclampsia
Screening tests –
Doppler ultrasound –high resistance index in
the uterine artery
Presence of diastolic notch – at 24 weeks
gestation in the uterine artery
Development of renal dysfunction –
hyperuricemia and microalbuminuria
15. Absence of end diastolic frequencies –
Average mean arterial pressure (MAP) in second
trimester more than or equal 90mmHg
Maternal serum level of sFlt -1 is increased
Fetal DNA- detection of free fetal DNA in
maternal plasma in early pregnancy
Proteomics ,metabolomics and transcryptomic
marker
Roll over test – an increase of 20mmHg in
diastolic pressure
16. Prophylactic measures for
prevention
Regular antenatal checkup
Antiplatelet agents –low dose aspirin 60mgdaily
it inhibit cyclo oxygenase in platelet ,preventing
formation of thromboxane
Low molecular weight heparin in thrombophilias
Calcium supplementation
Antioxidants – vitamins c and E , magnesium
,zinc , fish oil and low salt diet
Balance diet – increase protein ,reduce risk
17. Management of gestational
hypertension and pre eclampsia
Rest
Diet
Diuretics – furosemide 40mg ,orally after
breakfast for 5 days in a week
Antihypertensive drugs – methyldoma
Labetalol
Nifedipine
Hydralazine
19. Management of severe
preeclampsia
Group 1 (24-26)-usual management fail to
control ,pregnancy has to terminated after
proper counseling
Group 2(26-34)- depends on their clinical
response ,antihypertensive and steroids are
given for enhancement of fetal lung maturity
, pregnancy is terminated anytime if
parameter are unfavorable
20. Continue..
Group 3 (more than 34)- worsening of
biophysical or biochemical parameter
pregnancy is terminated ,NICU facility is
must to reduce perinatal mortality
21. Methods of delivery
Induction of labor
Indication of labor – aggravation of
preeclamptic feature along with epigaastric
pain
Hypertension persist inspite of medical
treatment with pregnancy reaching 37 weeks
Acute fulminating pre eclampsia
Tendency of pregnancy to overrun the
expected date
22. Cesarean section
Indication –
Urgent termination is indicated , cervix is
unfavorable (unripe and closed)
Associated complicating factors such as
elderly primigravidae , contracted pelvis
23. Management during labor
Patient should be in bed
Antihypertensive drugs are given
B.P and urinary output are to be noted
Careful monitoring of fetal wellbeing
24. Complication
Maternal –during pregnancy
1 . Eclampsia
2. Accidental hemorrhage
3. Oliguria and anuria
4. Dimness of vision and even blindness
5 . preterm labor
6. HELLP syndrome